MediGene AG: Presentation of EndoTAG(TM)-1 and oHSV Results at the 2009 American Society of Clinical Oncology Annual Meeting
Moreover the data obtained in the clinical trial of the oncolytic virus NV1020 in patients with colorectal cancer and liver metastases, as well as final data from a trial of the oncolytic virus G207 for the treatment of malignant brain tumors will be presented during two poster sessions. The posters are titled "Phase II efficacy results using an onkolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC)" (abstract no. 4089), and "Treatment of recurrent malignant glioma with G207. A genetically engineered herpes simplex virus-1, followed by irradiation: phase I study results" (abstract no. 2042). Both posters will be presented on Sunday, May 31, 2009 from 8.00 - 12.00 a.m. local time (5.00 p.m. CEST).
This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGene(TM) and EndoTAG(TM) are trademarks of MediGene AG. This trademark may be held or licensed for specific countries